Montoto-Marqués Antonio, Benito-Penalva Jesús, Ferreiro-Velasco María Elena, Andrew Wright Mark, Salvador-De la Barrera Sebastian, Kumru Hatice, Gaitán-Pérez Nelson, Hernández-Navarro Agustin, Rodríguez-Sotillo Antonio, Martins Braga Fernando, Palencia-Vidal Angela, Vidal-Samsó Joan
Unidad de Lesionados Medulares, Complejo Hospitalario Universitario de A Coruña, Grupo de Investigación en Terapia Celular y Medicina Regenerativa, Instituto de Investigación Biomédica de A Coruña (INIBIC), 15006 A Coruña, Spain.
Fundación Institut Guttmann, Institut Universitari de Neurorehabilitació Adscrit a la UAB, 08916 Barcelona, Spain.
J Clin Med. 2025 Mar 24;14(7):2203. doi: 10.3390/jcm14072203.
Recovery from traumatic spinal cord injury (tSCI) is challenging due to the limited regenerative capacity of the central nervous system to restore cells, myelin, and neural connections. At the clinical level, the fundamental pillars of treatment are the reduction in secondary damage (neuroprotection) and rehabilitation; these are the tools we have to mitigate the disability caused by spinal cord injury (SCI). To date, the treatments on which neuroprotection has been based are the prevention of acute respiratory failure to avoid hypoxia, early hemodynamic control, neuroprotective drugs and surgical management. Optimizing early hemodynamic control to ensure adequate spinal cord perfusion may be key to the management of SCI. While neuroprotective agents like methylprednisolone have fallen into disuse, several promising therapies are currently being tested in clinical trials. In terms of surgical treatment, although their impact on neurological recovery remains debated, appropriate early bone decompression followed by duroplasty in selected cases is increasingly recommended. Advances in cell therapies hold significant potential for enhancing both clinical and functional outcomes in SCI patients. Moreover, emerging neuromodulation techniques, such as transcutaneous and epidural stimulation, along with innovations in rehabilitation technologies-such as robotic systems and exoskeletons-are becoming indispensable tools for improving locomotion and overall mobility in individuals with SCI. This article provides an update on the advances in neuroprotection against secondary damage caused by tSCI, in cellular therapies, and in new rehabilitation therapies.
由于中枢神经系统恢复细胞、髓鞘和神经连接的再生能力有限,创伤性脊髓损伤(tSCI)的恢复具有挑战性。在临床层面,治疗的基本支柱是减少继发性损伤(神经保护)和康复;这些是我们减轻脊髓损伤(SCI)所致残疾的手段。迄今为止,神经保护所基于的治疗方法包括预防急性呼吸衰竭以避免缺氧、早期血流动力学控制、神经保护药物和手术治疗。优化早期血流动力学控制以确保脊髓有足够的灌注可能是SCI治疗的关键。虽然像甲基泼尼松龙这样的神经保护剂已不再使用,但目前有几种有前景的疗法正在临床试验中进行测试。在手术治疗方面,尽管其对神经恢复的影响仍存在争议,但越来越推荐在选定病例中进行适当的早期骨减压,随后进行硬脊膜成形术。细胞疗法的进展在改善SCI患者的临床和功能结局方面具有巨大潜力。此外,新兴的神经调节技术,如经皮和硬膜外刺激,以及康复技术的创新,如机器人系统和外骨骼,正成为改善SCI患者运动能力和整体活动能力不可或缺的工具。本文提供了有关针对tSCI所致继发性损伤的神经保护、细胞疗法和新康复疗法进展的最新情况。